A synopsis of modern-day colorectal cancer: Where we stand

被引:23
作者
Ranasinghe, Ranmali [1 ]
Mathai, Michael [1 ]
Zulli, Anthony [1 ]
机构
[1] Victoria Univ, Coll Hlth & Med, Inst Hlth & Sport, Melbourne, Vic, Australia
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2022年 / 1877卷 / 02期
关键词
Colorectal cancer; Epidemiology; Statistics; Chemotherapy; Immunotherapy; New findings; INFLAMMATORY-BOWEL-DISEASE; DNA MISMATCH REPAIR; MICROSATELLITE INSTABILITY; ULCERATIVE-COLITIS; FAMILY-HISTORY; YOUNG-ADULTS; COLON-CANCER; VITAMIN-D; CLINICAL-IMPLICATIONS; CIGARETTE-SMOKING;
D O I
10.1016/j.bbcan.2022.188699
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer (CRC) is a malignancy in the gastro-intestinal (GI) tract which has very limited treatment options still, despite the vast amount of research undertaken. CRC was first discovered a century ago and is the third-highest cause of global cancer-related deaths. Once diagnosed as a T4-stage carcinoma, the prognosis extends only up to two years at the best. Although resectable surgery remains the primary safeguard in combatting metastatic CRC, research had focussed on to various therapeutic and disease management strategies, such as stem cell -based therapies, CT, MRI, PET-CT scans, colonography, endoscopy and biologics. The struggle in developing an anti-cancer therapy may be due to its unresolved aetiology comprising of genetic abnormalities, and multiple risk factors in lifestyle, culture, and environment in the globally diverse, human populations. This review aims to summarize the prominent features of CRC which could encourage lifestyle changes and introduce novel clinically -relevant therapeutic strategies to improve its overall management.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Hemostatic Biomarkers and Cancer Prognosis: Where Do We Stand?
    Falanga, Anna
    Marchetti, Marina
    Russo, Laura
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2021, 47 (08) : 962 - 971
  • [32] Lung cancer in Eastern Morocco: where do we stand?
    Belmokhtar, Karam Yahya
    Tajir, Mariam
    Boulouiz, Redouane
    Bennani, Amal
    Brahmi, Sami Aziz
    Alloubi, Ihsan
    Kouismi, Hatim
    Kamaoui, Imane
    Skiker, Imane
    Afqir, Said
    Abda, Naima
    Bellaoui, Mohammed
    Mezouar, Loubna
    PAN AFRICAN MEDICAL JOURNAL, 2019, 34
  • [33] Immunotherapy in Head and Neck Cancer: Where Do We Stand?
    Natalia G. Vallianou
    Angelos Evangelopoulos
    Dimitris Kounatidis
    Fotis Panagopoulos
    Eleni Geladari
    Irene Karampela
    Theodora Stratigou
    Maria Dalamaga
    Current Oncology Reports, 2023, 25 : 897 - 912
  • [34] Targeting Angiogenesis in Cancer Treatments: Where do we Stand?
    Petrovic, N.
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2016, 19 (02): : 226 - 238
  • [35] TARGETING GUANYLATE CYCLASE C IN COLORECTAL CANCER: WHERE ARE WE NOW?
    Pattison, A. M.
    Abraham, T. S.
    Merlino, D. J.
    Lin, J. E.
    Saw, T. A.
    Snook, A. E.
    Waldman, S. A.
    DRUGS OF THE FUTURE, 2016, 41 (08) : 477 - 484
  • [36] Methylation markers in colorectal cancer: Where are we now?
    Khamas, Ahmed
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S34 - S34
  • [37] Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
    Moschetta, Michele
    Boussios, Stergios
    Rassy, Elie
    Samartzis, Eleftherios P.
    Funingana, Gabriel
    Uccello, Mario
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (24)
  • [38] Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review
    Grancher, Adrien
    Cuissy, Steven
    Girot, Helene
    Gillibert, Andre
    Di Fiore, Frederic
    Guittet, Lydia
    MOLECULAR ONCOLOGY, 2024, 18 (11) : 2629 - 2648
  • [39] Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
    Chintala, Lakshmi
    Vaka, Susmitha
    Baranda, Joaquina
    Williamson, Stephen K.
    ONCOLOGY REVIEWS, 2011, 5 (02) : 129 - 140
  • [40] Landscape of Biomarkers and Pathologic Response in Rectal Cancer: Where We Stand?
    Ocanto, Abrahams
    Teja, Macarena
    Amorelli, Francesco
    Counago, Felipe
    Palacios, Ariel Gomez
    Alcaraz, Diego
    Cantero, Ramon
    CANCERS, 2024, 16 (23)